Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients

By sjmartinez • May 7, 2024

Bardia A, Sun S, Thimmiah N, Coates JT, Wu B, Abelman RO, Spring L, Moy B, Ryan P, Melkonyan MN, Partridge A, Juric D, Peppercorn J, Parsons H, Wander SA, Attaya V, Lormil B, Shellock M, Nagayama A, Bossuyt V, Isakoff SJ, Tolaney SM, Ellisen LW. Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients. Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-24-0428. Epub ahead of print. PMID: 38709212.

Tags: Hematology/Oncology, Publications

RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Matsui[...]

Secondary Neuropathy From Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome: A Case Report

Young P, Kroloff M. Secondary Neuropathy From Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome: A Case Report. Cureus. 2025 Oct 21;17(10):e95064. doi:[...]

Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy

Duesberg MS, Schiller G. Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy. Cureus. 2025 Oct 21;17(10):e95112. doi: 10.7759/cureus.95112. PMID: 41281092;[...]